- Home
- AUDC vs FULC Comparison
AUDC vs FULC Comparison
Compare AUDC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- FULC
- Stock Information
- Founded
- AUDC 1992
- FULC 2015
- Country
- AUDC Israel
- FULC United States
- Employees
- AUDC N/A
- FULC N/A
- Industry
- AUDC Telecommunications Equipment
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- AUDC Utilities
- FULC Health Care
- Exchange
- AUDC Nasdaq
- FULC Nasdaq
- Market Cap
- AUDC 270.6M
- FULC 221.5M
- IPO Year
- AUDC 1999
- FULC 2019
- Fundamental
- Price
- AUDC $10.74
- FULC $3.96
- Analyst Decision
- AUDC Buy
- FULC Hold
- Analyst Count
- AUDC 2
- FULC 10
- Target Price
- AUDC $10.00
- FULC $7.44
- AVG Volume (30 Days)
- AUDC 113.5K
- FULC 1.0M
- Earning Date
- AUDC 02-04-2025
- FULC 02-25-2025
- Dividend Yield
- AUDC 3.35%
- FULC N/A
- EPS Growth
- AUDC 0.25
- FULC N/A
- EPS
- AUDC 0.40
- FULC N/A
- Revenue
- AUDC $244,181,000.00
- FULC $80,871,000.00
- Revenue This Year
- AUDC $1.06
- FULC $2,821.96
- Revenue Next Year
- AUDC $2.94
- FULC N/A
- P/E Ratio
- AUDC $26.75
- FULC N/A
- Revenue Growth
- AUDC N/A
- FULC 2987.86
- 52 Week Low
- AUDC $7.70
- FULC $2.86
- 52 Week High
- AUDC $14.45
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- AUDC 65.83
- FULC 41.64
- Support Level
- AUDC $9.46
- FULC $3.93
- Resistance Level
- AUDC $10.83
- FULC $5.17
- Average True Range (ATR)
- AUDC 0.29
- FULC 0.30
- MACD
- AUDC 0.08
- FULC -0.13
- Stochastic Oscillator
- AUDC 94.71
- FULC 3.97
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells advanced and converged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.